查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1875920

全球人類乳突病毒 (HPV) 檢測市場

Human Papillomavirus (HPV) Testing
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 173 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球人類乳突病毒（HPV）檢測市場預計到2030年將達到18億美元

全球人類乳突病毒 (HPV) 檢測市場預計在 2024 年達到 13 億美元，預計到 2030 年將達到 18 億美元，在分析期（2024-2030 年）內複合年成長率 (CAGR) 為 6.2%。本報告分析的細分市場之一「醫院和診所」預計將以 6.0% 的複合年成長率成長，並在分析期結束時達到 9.194 億美元。 「診斷中心」細分市場預計在分析期間將以 6.9% 的複合年成長率成長。

美國市場規模估計為3.527億美元，而中國市場預計將以5.8%的複合年成長率成長。

預計到2024年，美國乳突病毒（HPV）檢測市場規模將達3.527億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到2.845億美元，2024年至2030年的複合年成長率（CAGR）為5.8%。其他值得關注的區域市場分析包括日本和加拿大，預計在分析期間內，這兩個國家的複合年成長率分別為5.8%和5.1%。在歐洲，德國預計複合年成長率約為5.1%。

全球人類乳突病毒（HPV）檢測市場－主要市場趨勢與促進因素概述

人類乳突病毒（HPV）檢測能否成為預防子宮頸癌、改善女性健康的關鍵？

人類乳突病毒 (HPV) 檢測是女性健康促進計畫的基石，但為何它對預防子宮頸癌和改善整體健康狀況如此重要？ HPV 是世界上最常見的性行為感染傳染病，某些病毒株與子宮頸癌以及其他癌症（如咽癌、肛門癌和外陰癌）的發生直接相關。 HPV 檢測可以識別出可能導致這些癌症的高風險 HPV 類型，從而實現早期診斷和治療。

HPV檢測的意義在於它能夠在細胞癌變之前很久就檢測到高風險感染。透過HPV檢測早期發現高風險族群，可以及時採取適當的干涉措施，例如額外的診斷程序或疫苗接種等預防措施，從而預防子宮頸癌的發生。 HPV檢測與常規巴氏抹片檢查相結合，在降低子宮頸癌發生率和改善女性健康方面發揮重要作用。隨著人們對HPV在癌症發生發展中的作用認知不斷提高，廣泛開展HPV檢測已成為預防該病毒相關嚴重後果的重要公共衛生措施。

人類乳突病毒（HPV）檢測技術取得了哪些進展？

技術進步顯著提高了HPV檢測的敏感度、準確性和普及性，使其成為更有效的癌症預防和篩檢工具。其中一個最重要的進展是分子診斷技術的引入，例如聚合酵素鏈鎖反應（PCR）檢測，該技術能夠高精度地檢測HPV DNA。基於PCR的檢測可以識別特定的HPV株，使臨床醫生能夠區分高風險型和低危險型HPV。這種更高的特異性使得風險評估更加準確，並確保高風險族群得到適當的後續照護。

自動化檢測系統的引入簡化了HPV檢測流程，降低了人為誤差的可能性，並提高了臨床效率。自動化平台能夠快速、統一地處理大量檢體，使醫療機構更容易將HPV檢測納入常規篩檢計畫。這些進步有助於提高HPV檢測的可近性，即使在資源匱乏、人工處理困難的地區也是如此。

結合HPV檢測和傳統巴氏抹片檢查（細胞學檢查）的聯合檢測已被證實是子宮頸癌篩檢的有效策略。聯合檢測使醫護人員能夠同時篩檢異常子宮頸細胞和高危險型HPV，進而提高篩檢計畫的準確性。這種雙重篩檢方法提高了子宮頸癌前病變的檢出率，並有助於更早識別子宮頸癌高風險女性。

另一項重要的技術進步是開發了HPV自採集檢測方法，使人們能夠在家中自行採集HPV樣本。自採集試劑盒包含採集陰道拭子所需的說明和設備，採集的樣本隨後會被送往檢測實驗室。這項創新擴大了HPV檢測的覆蓋範圍，使那些難以獲得傳統醫療服務的群體，例如居住在偏遠地區或不願接受臨床檢測的人群，也能獲得檢測服務。研究表明，自採集檢體的準確性幾乎與醫護人員採集的檢體相當，使其成為提高HPV篩檢普及率的一種很有前景的工具。

數位健康工具的進步也促進了HPV檢測的改進。行動應用程式和線上平台幫助人們追蹤篩檢計畫、接收檢測結果，並取得HPV和子宮頸癌預防的教育資源。這些數位工具提高了患者的參與度，使人們更容易了解自身健康狀況並積極主動地進行健康管理。

液基細胞學（LBC）是HPV檢測的另一項改進。與依賴玻片的傳統巴氏抹片檢查不同，LBC將細胞懸浮於液體中，從而提供更全面、更清晰的樣本。此方法不僅提高了異常細胞檢出的準確性，而且允許在同一樣本上進行HPV檢測，從而提高了篩檢效率。 LBC已廣泛應用於子宮頸癌篩檢計畫中，有助於減少假陰性結果，並能更早識別出HPV相關異常的女性。

為什麼人類乳突病毒（HPV）檢測對子宮頸癌預防和公共衛生至關重要？

HPV檢測對於子宮頸癌的預防至關重要，因為它能夠及早發現高危險型HPV感染，而高危險型HPV感染是子宮頸癌的主要致病因子。透過在子宮頸發生癌變或癌前病變之前識別感染者，HPV檢測為早期療育提供了機會，包括加強後續觀察、後續檢測以及對異常細胞進行治療。這種早期發現對於降低子宮頸癌的發生率至關重要，而子宮頸癌也是最可預防的癌症之一，可以透過適當的篩檢和疫苗接種來預防。

子宮頸癌是一個緩慢發展的過程，通常始於子宮頸細胞的癌前病變。 HPV檢測可以檢測出最有可能導致這些病變的高風險病毒株，從而在巴氏抹片檢查發現病變之前就發現它們。這使得醫護人員能夠更密切後續觀察患者，並降低子宮頸癌未被發現的風險。 HPV檢測對於30歲以上的女性尤其重要，因為在這個年齡段，持續性HPV感染更容易導致子宮頸癌。

HPV檢測對公共衛生至關重要，有助於降低HPV相關癌症的整體負擔。除子宮頸癌外，高危險型HPV也與其他癌症有關，包括肛門癌、口咽癌（喉癌）和陰莖癌。雖然子宮頸癌篩檢是HPV檢測最成熟的應用，但目前仍在研究如何將HPV檢測應用於其他癌症的篩檢，尤其是在高風險族群中。

HPV檢測在預防保健中的作用不僅限於診斷。 HPV檢測在指導疫苗接種工作中也扮演重要角色。 HPV人類乳突病毒(HPV)疫苗的引入顯著降低了高危險型HPV感染率和子宮頸癌發生率。然而，由於並非所有人都接種了疫苗，且疫苗在接觸HPV病毒前接種最為有效，因此仍需定期進行檢測，以發現未接種疫苗或部分接種疫苗人群的感染情況。 HPV檢測有助於確定接種疫苗後個體是否仍感染高危險型HPV，從而確保他們獲得必要的後續照護。

將HPV檢測納入更廣泛的子宮頸癌篩檢項目，並提高了全球預防性護理的有效性。子宮頸癌仍然是許多國家女性死亡的主要原因之一，尤其是在醫療資源匱乏的地區。與單獨的巴氏抹片檢查相比，HPV檢測在檢測癌前病變方面更加靈敏可靠，即使在資源匱乏的環境中也能幫助識別高風險族群。 HPV自取樣檢測的引入進一步擴大了篩檢的覆蓋範圍，無需面診，有助於消除農村和醫療服務不足地區的障礙。

雖然男性接受常規HPV檢測的普及程度不如女性，但高風險族群（例如男男性行為者）對HPV相關癌症的認知正在不斷提高。由於HPV感染是這些族群的重要風險因素，HPV檢測擴大被用於肛門癌篩檢。透過將HPV檢測推廣到女性以外的其他族群，醫療系統有望進一步降低整個人群中HPV相關癌症的發生率。

哪些因素正在推動人類乳突病毒（HPV）檢測市場的成長？

HPV檢測市場的成長受多種因素驅動，包括HPV感染率的上升趨勢、子宮頸癌預防意識的增強以及檢測技術的進步。其中一個主要促進因素是人們越來越意識到早期檢測在預防HPV相關癌症的重要性。隨著公共衛生宣傳活動不斷強調定期篩檢和疫苗接種的益處，越來越多的人將HPV檢測納入日常醫療保健計劃。這增加了對HPV檢測服務的需求，尤其是在已建立子宮頸癌篩檢計畫的國家。

市場成長也得益於全​​球疫苗接種計畫的擴展，尤其是人類乳突病毒(HPV)疫苗的推廣。隨著疫苗接種覆蓋率的提高，HPV檢測對於監測疫苗的長期有效性以及識別未接種或部分接種人群中的感染情況仍然至關重要。在已開展人類乳突病毒(HPV)疫苗疫苗接種計畫的國家，HPV檢測在追蹤疫苗對HPV感染率的影響以及指導公共衛生政策方面發揮關鍵作用。

HPV檢測技術的進步提高了檢測的準確性、普及性和效率，進一步推動了市場需求。基於PCR的檢測、自動化檢測平台和自採集試劑盒等創新技術使HPV檢測更加便捷可靠，擴大了其在臨床和家庭環境中的應用。特別是自採集HPV檢測的發展，隨著更多國家採用這些方法，預計將持續推動市場成長，擴大篩檢覆蓋範圍，尤其是在服務不足的地區。

政府旨在降低子宮頸癌發生率的主導和公共衛生計畫也是推動市場成長要素的關鍵因素。在許多地區，醫療衛生系統正從傳統的子宮頸癌子宮頸抹片檢查—過渡到HPV檢測，後者在檢測高風險感染方面具有更高的靈敏度。尤其是在醫療衛生系統較為發達的國家，預計HPV篩檢在國家篩檢計畫中的應用將顯著增加，從而進一步推動市場成長。

對個人化醫療日益成長的需求也推動了HP​​V檢測市場的成長。隨著精準醫療的重要性日益凸顯，人們對考慮個人獨特風險因素的個人化篩檢和預防策略越來越感興趣。 HPV檢測透過識別高風險族群並據此制定個人化的後續照護方案，為子宮頸癌篩檢提供了更個人化的方法。隨著醫療保健系統朝向更個人化的照護模式發展，這一趨勢預計將持續下去，因為像HPV篩檢這樣的檢測在疾病預防中發揮關鍵作用。

除子宮頸癌外，HPV相關癌症的增加也是推動市場成長的因素之一。雖然HPV檢測的主要目標是子宮頸癌，但該病毒也會導致其他癌症，例如肛門癌、口咽癌和陰莖癌。隨著人們對這些HPV相關癌症的認知不斷提高，尤其是在高風險族群中，預計除傳統子宮頸癌篩檢外，對HPV檢測的需求將會擴大，為市場創造新的成長機會。

由於技術進步、公眾健康意識的提高以及HPV檢測被納入國家篩檢計劃，HPV檢測市場預計將持續擴張。隨著醫療保健系統日益重視早期發現和預防性護理，HPV檢測仍將是降低HPV相關癌症發生率和改善全球健康狀況的關鍵工具。

部分：

依最終使用者（醫院/診所、診斷中心、研究機構）分類

受訪公司範例

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Arbor Vita Corporation
  • Becton, Dickinson & Company
  • Cepheid, Inc.
  • Daan Gene Co., Ltd.
  • Diagcor Bioscience Incorporation Ltd.
  • Enzo Biochem, Inc.
  • F. Hoffmann-La Roche AG
  • Fujirebio US, Inc.
  • Greiner Bio-One International GmbH
  • Hologic, Inc.
  • Hybribio Limited
  • Medical & Biological Laboratories Co. Ltd.
  • Norgen Biotek Corporation
  • Promega Corporation
  • Qiagen NV
  • Seegene, Inc.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • Zytovision GmbH

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具來變革市場和競爭情報。

Market Glass, Inc. 沒有採用查詢LLM 或產業專用的SLM 的常見做法，而是建立了一個由世界各地領域專家精心策劃的內容庫，其中包括影片轉錄、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

在最新發布的報告中，Market Glass, Inc. 將關稅對地理市場的影響納入考量，並根據公司總部所在國、製造地以及進出口（成品和OEM產品）情況，預測企業競爭格局的變化。這種複雜多變的市場現實將對競爭對手產生多方面的影響，包括銷貨成本增加、盈利下降和供應鏈重組，同時也會影響微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 世界其他地區

第4章 競賽

簡介目錄
Product Code: MCP12454

Global Human Papillomavirus (HPV) Testing Market to Reach US$1.8 Billion by 2030

The global market for Human Papillomavirus (HPV) Testing estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Hospitals & Clinics End-Use, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$919.4 Million by the end of the analysis period. Growth in the Diagnostic Centers End-Use segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$352.7 Million While China is Forecast to Grow at 5.8% CAGR

The Human Papillomavirus (HPV) Testing market in the U.S. is estimated at US$352.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$284.5 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.8% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Human Papillomavirus (HPV) Testing Market - Key Trends and Drivers Summarized

Is Human Papillomavirus (HPV) Testing the Key to Preventing Cervical Cancer and Improving Women's Health?

Human papillomavirus (HPV) testing has become a cornerstone of women’s health initiatives, but why is it so essential for preventing cervical cancer and improving overall healthcare outcomes? HPV is the most common sexually transmitted infection worldwide, and certain strains of the virus are directly linked to the development of cervical cancer, as well as other cancers such as those affecting the throat, anus, and genital areas. HPV testing identifies the presence of high-risk HPV strains that can cause these cancers, enabling earlier diagnosis and treatment.

The significance of HPV testing lies in its ability to detect high-risk infections long before cancerous changes occur in the cells. Early detection through HPV testing can prevent the development of cervical cancer by identifying those at risk and guiding timely intervention, such as further diagnostic procedures or preventive measures like vaccines. In combination with regular screening via Pap smears, HPV testing plays a critical role in reducing cervical cancer rates and improving women’s health. As awareness of HPV's role in cancer grows, widespread HPV testing has become a key public health measure in preventing serious outcomes related to this virus.

How Has Technology Advanced Human Papillomavirus (HPV) Testing?

Technological advancements have significantly improved the sensitivity, accuracy, and accessibility of HPV testing, making it a more effective tool for cancer prevention and screening. One of the most important developments is the introduction of molecular diagnostic techniques, such as polymerase chain reaction (PCR) testing, which can detect HPV DNA with high precision. PCR-based tests are able to identify the specific strains of HPV that are present, allowing clinicians to differentiate between high-risk and low-risk strains. This level of specificity enables more accurate risk assessment and ensures that individuals with high-risk infections receive appropriate follow-up care.

The integration of automated testing systems has also streamlined the process of HPV testing, reducing the potential for human error and improving efficiency in clinical settings. Automated platforms can process large volumes of samples quickly and consistently, making it easier for healthcare providers to incorporate HPV testing into routine screening programs. These advancements have also made HPV testing more accessible in low-resource settings, where manual processing might be less feasible.

Co-testing, which combines HPV testing with traditional Pap smears (cytology), has emerged as an effective strategy for cervical cancer screening. Co-testing allows healthcare providers to simultaneously screen for abnormal cervical cells and the presence of high-risk HPV strains, improving the accuracy of screening programs. This dual approach has been shown to increase the detection of precancerous changes in the cervix, ensuring that women at risk for cervical cancer are identified earlier.

Another significant technological advancement is the development of self-sampling HPV tests, which allow individuals to collect their own samples at home. Self-sampling kits contain instructions and tools for collecting a vaginal swab, which can then be sent to a lab for analysis. This innovation improves access to HPV testing, particularly for individuals who may face barriers to traditional healthcare settings, such as those living in remote areas or those who are uncomfortable with clinical exams. Research has shown that self-sampling tests are nearly as accurate as clinician-collected samples, making them a promising tool for increasing HPV screening coverage.

Advances in digital health tools have also played a role in improving HPV testing. Mobile apps and online platforms can help individuals track their screening schedules, receive test results, and access educational resources about HPV and cervical cancer prevention. These digital tools enhance patient engagement, making it easier for individuals to stay informed and proactive about their health.

Liquid-based cytology (LBC) is another improvement in HPV testing. Unlike traditional Pap smears, which rely on a slide sample, LBC suspends cells in liquid, providing a more comprehensive and clear sample for testing. This method not only allows for more accurate detection of abnormal cells but also enables the same sample to be tested for HPV, offering a streamlined approach to screening. LBC has been widely adopted in cervical cancer screening programs, helping to reduce false-negative results and ensuring that women with HPV-related abnormalities are identified early.

Why Is Human Papillomavirus (HPV) Testing Critical for Cervical Cancer Prevention and Public Health?

HPV testing is critical for cervical cancer prevention because it allows for the early detection of high-risk HPV infections, which are the leading cause of cervical cancer. By identifying individuals with these infections before any cancerous or precancerous changes occur in the cervix, HPV testing provides an opportunity for early intervention, such as increased monitoring, follow-up testing, or treatment of abnormal cells. This early detection is essential for reducing the incidence of cervical cancer, which remains one of the most preventable cancers with proper screening and vaccination.

Cervical cancer develops slowly over time, often starting with precancerous changes in the cells of the cervix. HPV testing can detect the presence of high-risk strains of the virus that are most likely to lead to these changes, even before visible abnormalities are detected on a Pap smear. This allows healthcare providers to monitor at-risk individuals more closely, reducing the chances of cervical cancer developing unnoticed. For women aged 30 and older, HPV testing is especially critical, as persistent HPV infections are more likely to cause cervical cancer in this age group.

HPV testing is also essential for public health because it can help reduce the overall burden of HPV-related cancers. Beyond cervical cancer, high-risk HPV strains are associated with other types of cancers, including anal, oropharyngeal (throat), and penile cancers. While cervical cancer screening is the most well-established use of HPV testing, research is ongoing to explore how HPV testing can be applied to other types of cancer screenings, particularly in populations at high risk.

The role of HPV testing in preventive care extends beyond diagnosis. HPV testing also plays a crucial role in guiding vaccination efforts. The introduction of the HPV vaccine has dramatically reduced the rates of high-risk HPV infections and cervical cancer in vaccinated populations. However, because not everyone receives the vaccine, and it is most effective when administered before exposure to HPV, regular testing remains necessary to catch infections that occur in unvaccinated or partially vaccinated individuals. HPV testing can help determine whether individuals are infected with high-risk strains even after vaccination, ensuring that they receive the necessary follow-up care.

The integration of HPV testing with broader cervical cancer screening programs has improved the effectiveness of preventive care worldwide. In many countries, cervical cancer remains a leading cause of death among women, particularly in regions with limited access to healthcare. HPV testing offers a more sensitive and reliable method for detecting precancerous changes than Pap smears alone, helping to identify high-risk individuals in low-resource settings. The use of self-sampling HPV tests further enhances access to screening by removing the need for in-person clinical visits, which can be a barrier in rural or underserved communities.

For men, while routine HPV testing is not as widespread, it is becoming more recognized in populations at high risk for HPV-related cancers, such as men who have sex with men (MSM). HPV testing is increasingly used to screen for anal cancer in these groups, where HPV infections are a significant risk factor. By expanding HPV testing beyond women, healthcare systems can further reduce the incidence of HPV-related cancers across all populations.

What Factors Are Driving the Growth of the Human Papillomavirus (HPV) Testing Market?

Several factors are driving the growth of the HPV testing market, including the rising prevalence of HPV infections, increased awareness of cervical cancer prevention, and advancements in testing technologies. One of the primary drivers is the growing recognition of the importance of early detection in preventing HPV-related cancers. As public health campaigns continue to emphasize the benefits of regular screening and vaccination, more individuals are seeking out HPV testing as part of their routine healthcare. This has led to increased demand for HPV testing services, particularly in countries with established cervical cancer screening programs.

The global expansion of vaccination programs, particularly for the HPV vaccine, is also driving market growth. As vaccination coverage increases, HPV testing remains crucial for monitoring the long-term effectiveness of vaccines and identifying infections in unvaccinated or partially vaccinated populations. In countries where HPV vaccination programs are being implemented, HPV testing is playing an essential role in tracking the impact of the vaccine on HPV infection rates and guiding public health policies.

Technological advancements in HPV testing have made these tests more accurate, accessible, and efficient, further boosting market demand. Innovations such as PCR-based tests, automated testing platforms, and self-sampling kits have made HPV testing more convenient and reliable, increasing uptake in both clinical and home settings. The development of self-sampling HPV tests, in particular, has expanded access to screening, especially in underserved communities, and is expected to continue driving growth in the market as more countries adopt these methods.

Government initiatives and public health programs aimed at reducing cervical cancer rates are another significant driver. In many regions, healthcare systems are shifting from traditional Pap smears to HPV testing as the primary method of cervical cancer screening, reflecting the superior sensitivity of HPV tests in detecting high-risk infections. The adoption of HPV primary screening in national screening programs is expected to increase significantly, particularly in countries with well-developed healthcare systems, driving further growth in the market.

Rising demand for personalized healthcare is also influencing the growth of the HPV testing market. As precision medicine becomes more prominent, there is growing interest in personalized screening and prevention strategies that take into account an individual’s unique risk factors. HPV testing offers a more individualized approach to cervical cancer screening by identifying those at highest risk and tailoring follow-up care accordingly. This trend is likely to continue as healthcare systems shift toward more personalized models of care, where tests like HPV screening play a crucial role in disease prevention.

The increasing prevalence of HPV-related cancers beyond cervical cancer is another factor driving market growth. While cervical cancer is the primary focus of HPV testing, the virus is also responsible for other cancers, including anal, oropharyngeal, and penile cancers. As awareness of these HPV-related cancers grows, particularly in high-risk populations, demand for HPV testing is expected to expand beyond traditional cervical cancer screening, creating new opportunities for growth in the market.

With advancements in technology, growing public health awareness, and the integration of HPV testing into national screening programs, the HPV testing market is poised for continued expansion. As healthcare systems increasingly prioritize early detection and preventive care, HPV testing will remain a critical tool for reducing the incidence of HPV-related cancers and improving health outcomes worldwide.

SCOPE OF STUDY:

The report analyzes the Human Papillomavirus (HPV) Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

End-Use (Hospitals & Clinics, Diagnostic Centers, Research Institutes)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 46 Featured) -

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Arbor Vita Corporation
  • Becton, Dickinson & Company
  • Cepheid, Inc.
  • Daan Gene Co., Ltd.
  • Diagcor Bioscience Incorporation Ltd.
  • Enzo Biochem, Inc.
  • F. Hoffmann-La Roche AG
  • Fujirebio US, Inc.
  • Greiner Bio-One International GmbH
  • Hologic, Inc.
  • Hybribio Limited
  • Medical & Biological Laboratories Co. Ltd.
  • Norgen Biotek Corporation
  • Promega Corporation
  • Qiagen NV
  • Seegene, Inc.
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • Zytovision GmbH

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Global Economic Update
    • Human Papillomavirus (HPV) Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Cervical Cancer Prevention Drives Growth in Human Papillomavirus (HPV) Testing Market
    • Expansion of HPV Vaccination Programs Spurs Adoption of HPV Testing in Screening Initiatives
    • Role of HPV Testing in Enhancing Early Detection and Cancer Prevention Strengthens Business Case for Adoption
    • Increasing Focus on Point-of-care HPV Testing and Self-sampling Kits Fuels Market Demand
    • Growth in Use of HPV Testing for Other Cancers, Including Anal and Oropharyngeal, Expands Market Opportunities
    • Growth in Demand for Co-testing (HPV and Cytology) in Cervical Cancer Screening Fuels Adoption
    • Technological Advancements in Liquid-based Cytology and Multiplex Testing Drive Market Innovation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Human Papillomavirus (HPV) Testing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Human Papillomavirus (HPV) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Human Papillomavirus (HPV) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: USA 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: Canada 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • JAPAN
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: Japan 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • CHINA
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: China 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • EUROPE
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Human Papillomavirus (HPV) Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for Human Papillomavirus (HPV) Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Europe 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • FRANCE
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: France 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • GERMANY
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Germany 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Italy 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: UK 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Rest of Europe Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Rest of Europe 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Human Papillomavirus (HPV) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Asia-Pacific Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Asia-Pacific 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Rest of World Historic Review for Human Papillomavirus (HPV) Testing by End-Use - Hospitals & Clinics, Diagnostic Centers and Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Rest of World 15-Year Perspective for Human Papillomavirus (HPV) Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers and Research Institutes for the Years 2015, 2025 & 2030

IV. COMPETITION